Latest news with #GeorgeLeMaitre
Yahoo
16-05-2025
- Business
- Yahoo
LMAT Q1 Earnings Call: Sales Growth Outpaces Expectations, Margin Pressures Addressed
Medical device company LeMaitre Vascular (NASDAQ:LMAT) beat Wall Street's revenue expectations in Q1 CY2025, with sales up 12% year on year to $59.87 million. The company expects next quarter's revenue to be around $62.5 million, close to analysts' estimates. Its GAAP profit of $0.48 per share was 4.6% below analysts' consensus estimates. Is now the time to buy LMAT? Find out in our full research report (it's free). Revenue: $59.87 million vs analyst estimates of $57.75 million (12% year-on-year growth, 3.7% beat) EPS (GAAP): $0.48 vs analyst expectations of $0.50 (4.6% miss) Adjusted EBITDA: $16.78 million vs analyst estimates of $15.57 million (28% margin, 7.8% beat) The company lifted its revenue guidance for the full year to $245.5 million at the midpoint from $239.1 million, a 2.7% increase EPS (GAAP) guidance for the full year is $2.16 at the midpoint, missing analyst estimates by 3.5% Operating Margin: 21.1%, down from 22.2% in the same quarter last year Free Cash Flow Margin: 12.8%, up from 6.9% in the same quarter last year Organic Revenue rose 13% year on year (11% in the same quarter last year) Market Capitalization: $1.88 billion LeMaitre's first quarter results were driven by broad-based sales growth across all product categories and geographies, fueled by strong demand for vascular grafts and carotid shunts. Management attributed the outperformance to price increases, expansion of the direct sales force, and new international offices. CEO George LeMaitre emphasized, 'Growth was led by grafts up 17% and carotid shunts up 14%,' and noted record sales in every major product category. Looking ahead, management raised full-year revenue guidance, citing sustained sales momentum, the launch of new international offices, and recently secured regulatory approvals. While the company expects to benefit from a growing sales organization and upcoming product launches, management was cautious about potential margin headwinds from product mix and tariffs. CFO Dorian LeBlanc stated that moving away from the Elutia patch distribution agreement should improve organic growth and margins in the coming quarters. LeMaitre's management identified several operational and market drivers behind the quarter's results and discussed strategic moves to sustain momentum. Direct Sales Force Expansion: The company increased its on-payroll sales representatives to 164, aiming for 170 by year-end. Management highlighted that direct sales are their primary growth engine, with new hires expected to support continued market penetration. International Office Openings: New sales offices in Switzerland, Portugal, and soon the Czech Republic are expected to streamline distribution and improve sales in these regions. The Zurich office, for example, is designed to reduce customs complexity for Swiss hospitals, and direct offices have historically led to higher sales performance. Autograft Regulatory Progress: The company received a Medical Device Regulation (MDR) CE mark for its Artegraft product, enabling a European launch. Artegraft, previously the company's largest U.S. product, is now positioned for growth internationally, with additional approvals anticipated in Australia, Canada, Singapore, and Korea. Product Mix and Margin Impact: A shift toward higher sales in the graft category, which carries a lower gross margin than other products, contributed to a slight year-on-year decrease in operating margin. Management explained that price increases and reduced inventory scrap partially offset this impact. Elutia Patch Exit: LeMaitre exited its distribution agreement with Elutia to focus on its own biologics. This move is expected to improve organic growth rates and gross margins, as the discontinued product had been declining and carried lower margins than proprietary offerings. Management expects continued revenue growth, supported by an expanded sales force, new product approvals, and a broader international presence. However, product mix, tariffs, and competitive dynamics may create margin variability in upcoming quarters. Sales Force Investments: The addition of new sales representatives and managers is anticipated to drive higher revenues, with management indicating that new hires reach productivity levels comparable to veteran employees more quickly than in previous years. Tariff and Trade Risks: While LeMaitre manufactures all products in the United States, potential retaliatory tariffs remain a risk for international sales. Management believes they can mitigate much of the impact through price increases and low substitution risk due to niche product offerings. Product Launches and Regulatory Approvals: New product launches, such as the European rollout of Artegraft and expected approvals for RestoreFlow allografts in Ireland or Germany, are likely to support revenue growth and help offset potential margin headwinds from product mix changes. Suraj Kalia (Oppenheimer): Asked what gives management confidence to raise guidance given global uncertainties such as tariffs. CEO George LeMaitre cited stronger-than-expected Q1 results, effective price increases, and the positive impact of exiting the Elutia distribution. Rick Wise (Stifel): Inquired about the sustainability of price and volume growth. Management explained that Q1 saw a 9% price increase and 4% unit growth, but cautioned that future quarters may not maintain the same pace. Michael Saccone (Jefferies): Sought clarification on margin pressures. Management attributed margin contraction to higher sales in grafts, which have lower corporate-average margins, and highlighted that product mix shifts were a primary factor. Frank Tarkinen (Lake Street): Questioned when the expanded sales force would contribute to operating leverage. CFO Dorian LeBlanc noted that new reps ramp up productivity faster than in the past, and sales ramp and margin improvement are expected in the second half of the year. Brett Fishbin (KeyBanc): Asked about the impact of tariffs and the rationale for discontinuing the Elutia agreement. Management confirmed that expected tariff costs and mitigation strategies are factored into guidance, and explained that exiting Elutia removes a declining product and should support organic growth. In the coming quarters, the StockStory team will be monitoring (1) the impact of new direct sales offices and additional sales hires on revenue growth, (2) the European launch and adoption of Artegraft following regulatory approval, and (3) progress toward RestoreFlow allograft approvals in key European markets. Additionally, we will track management's ability to navigate product mix challenges and tariff risks while maintaining or expanding margins. LeMaitre currently trades at a forward P/E ratio of 35.9×. At this valuation, is it a buy or sell post earnings? See for yourself in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
Yahoo
07-05-2025
- Business
- Yahoo
Q1 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables
Let's dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q1 surgical equipment & consumables - specialty earnings season. The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly. The 4 surgical equipment & consumables - specialty stocks we track reported a slower Q1. As a group, revenues beat analysts' consensus estimates by 1.8% while next quarter's revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 8.8% since the latest earnings results. LeMaitre (NASDAQ:LMAT) Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions. LeMaitre reported revenues of $59.87 million, up 12% year on year. This print exceeded analysts' expectations by 3.7%. Despite the top-line beat, it was still a mixed quarter for the company with full-year revenue guidance exceeding analysts' expectations but a miss of analysts' EPS estimates. Chairman/CEO George LeMaitre said, 'Q1 sales momentum allows us to increase our 2025 reported ($245mm) and organic (+13%) sales guidance, up from prior guidance of $239mm and 10%. $303mm of cash also provides strategic optionality.' LeMaitre Total Revenue LeMaitre achieved the biggest analyst estimates beat and highest full-year guidance raise of the whole group. Still, the market seems discontent with the results. The stock is down 12.8% since reporting and currently trades at $80.52. Is now the time to buy LeMaitre? Access our full analysis of the earnings results here, it's free.
Yahoo
01-05-2025
- Business
- Yahoo
LeMaitre Q1 2025 Financial Results
BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic) Gross margin 69.2%, +60 bps Op. income $12.6mm, +6% Op. margin 21% Earnings per diluted share $0.48, +10% Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm was up 6% in Q1. Operating expenses grew 16% largely due to personnel expenses. The Company currently employs 164 sales representatives and 34 sales managers. Artegraft received its MDR CE Mark on April 29, and the European launch will begin presently. Artegraft, a biologic graft used in AV access and peripheral bypass, is the Company's largest U.S. product, with $37mm in U.S. sales in 2024. The Company ended its Elutia (formerly known as Aziyo Biologics) porcine patch distribution agreement on April 30. U.S. hospital sales were $5.0mm in 2024. Chairman/CEO George LeMaitre said, 'Q1 sales momentum allows us to increase our 2025 reported ($245mm) and organic (+13%) sales guidance, up from prior guidance of $239mm and 10%. $303mm of cash also provides strategic optionality.' Business Outlook Q2 2025 Guidance Full Year Guidance Sales $61.5mm - $63.5mm(Mid: $62.5mm, +12%, +12% Org.) $242mm - $249mm(Mid: $245mm, +12%, +13% Org.) Gross Margin 69.5% 69.6% Op. Income $14.6mm - $16.0mm(Mid: $15.3mm, +7%) $55.1mm - $60.3mm(Mid: $57.7mm, +10%) Op. Margin (Mid) 24% 24% EPS $0.55 - $0.59(Mid: $0.57, +10%) $2.07 - $2.24(Mid: $2.16, +12%) Quarterly Dividend On April 29, 2025, the Company's Board of Directors approved a quarterly dividend of $0.20/share of common stock. The dividend will be paid on May 29, 2025, to stockholders of record on May 15, 2025. Share Repurchase Program On February 18, 2025, the Company's Board of Directors authorized the repurchase of up to $75.0mm of the Company's common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 17, 2026, unless extended by the Board. Conference Call Reminder Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at For individuals unable to join the live conference call, a replay will be available on the Company's website. A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release. About LeMaitre LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company. For more information about the Company, please visit Use of Non-GAAP Financial Measures LeMaitre management believes that in order to better understand the Company's short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP financial performance measures. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release. In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events. The non-GAAP profitability metrics provided herein allow the company to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that the presentation of guidance described above for sales, operating income, and EPS provides an alternative and meaningful view of the Company's profitability. Forward-Looking Statements The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, competition from other medical device companies and alternative medical technologies; our ability to source, acquire, and integrate acquisitions; our ability to increase the selling prices of our products; our ability to maintain historic levels of profit growth; our dependence on sole- or limited-source suppliers; our implementation of our new enterprise resource planning system; disruptions to our information technology systems or breaches of our information security systems; our ability to engage sales call points other than vascular surgeons; our ability to procure, process, and preserve human tissue and comply with relevant regulatory requirements; the impact of a disruption in our manufacturing facilities; our ability to navigate the risks inherent in operating internationally; our ability to transition to direct sales models in certain international territories; the status of our regulatory approvals and compliance with regulatory requirements to market and sell our products both domestically and internationally; the occurrence of litigation relating to product liability, employment matters, intellectual property, contract disputes, and other commercial matters; the occurrence of product defects or recalls; our ability to service and repurchase our debt; the dilutive effect of a conversion of our debt; our ability to navigate executive officer transitions and retain key personnel; our ability to protect our intellectual property; and volatility in the price of our common stock; and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at and on the SEC's website at Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED BALANCE SHEETS (amounts in thousands) March 31, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 25,340 $ 25,610 Short-term marketable securities 277,209 274,112 Accounts receivable, net 35,112 30,063 Inventory and other deferred costs 65,906 64,927 Prepaid expenses and other current assets 4,546 7,480 Total current assets 408,113 402,192 Property and equipment, net 25,106 24,800 Right-of-use leased assets 16,233 16,768 Goodwill 65,945 65,945 Other intangibles, net 34,399 35,819 Deferred tax assets 1,037 1,425 Other assets 5,173 4,868 Total assets $ 556,006 $ 551,817 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,181 $ 1,761 Accrued expenses 19,929 24,732 Acquisition-related obligations - 1,433 Lease liabilities - short-term 2,635 2,681 Total current liabilities 24,745 30,607 Convertible senior notes, net 167,984 167,772 Lease liabilities - long-term 14,742 15,232 Deferred tax liabilities 88 85 Other long-term liabilities 875 831 Total liabilities 208,434 214,527 Stockholders' equity Common stock 242 242 Additional paid-in capital 217,118 213,760 Retained earnings 151,584 145,090 Accumulated other comprehensive loss (5,153 ) (6,184 ) Treasury stock (16,219 ) (15,618 ) Total stockholders' equity 347,572 337,290 Total liabilities and stockholders' equity $ 556,006 $ 551,817 LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (amounts in thousands, except per share amounts) (unaudited) For the three months ended March 31, 2025 March 31, 2024 Net sales $ 59,871 $ 53,478 Cost of sales 18,451 16,813 Gross profit 41,420 36,665 Operating expenses: Sales and marketing 14,212 11,686 General and administrative 10,487 9,013 Research and development 4,095 4,092 Total operating expenses 28,794 24,791 Income from operations 12,626 11,874 Other income (expense): Interest income 2,903 1,001 Interest expense (1,290 ) - Other income (loss), net 2 (78 ) Income before income taxes 14,241 12,797 Provision for income taxes 3,230 2,910 Net income $ 11,011 $ 9,887 Earnings per share of common stock Basic $ 0.49 $ 0.44 Diluted $ 0.48 $ 0.44 Weighted - average shares outstanding: Basic 22,570 22,365 Diluted 22,899 22,570 Cash dividends declared per common share $ 0.20 $ 0.16 LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) SELECTED NET SALES INFORMATION (amounts in thousands) (unaudited) For the three months ended March 31, 2025 March 31, 2024 $ % $ % Net Sales by Geography Americas $ 38,958 65 % $ 35,245 66 % Europe, Middle East and Africa 16,959 28 % 14,395 27 % Asia Pacific 3,954 7 % 3,838 7 % Total Net Sales $ 59,871 100 % $ 53,478 100 % LEMAITRE VASCULAR, INC (NASDAQ: LMAT) NON-GAAP FINANCIAL MEASURES (amounts in thousands) (unaudited) For the three months ended March 31, 2025 March 31, 2024 Reconciliation between GAAP and Non-GAAP EBITDA Net income as reported $ 11,011 $ 9,887 Interest (income) expense, net (1,613 ) (1,001 ) Amortization and depreciation expense 2,552 2,382 Provision for income taxes 3,230 2,910 EBITDA $ 15,180 $ 14,178 EBITDA percentage increase 7% LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) NON-GAAP FINANCIAL MEASURES (amounts in thousands) (unaudited) Reconciliation between GAAP and Non-GAAP sales growth: For the three months ended March 31, 2025 Net sales as reported $ 59,871 Impact of currency exchange rate fluctuations 754 Adjusted net sales $ 60,625 For the three months ended March 31, 2024 Net sales as reported $ 53,478 Adjusted net sales $ 53,478 Adjusted net sales increase for the three months ended March 31, 2025 $ 7,147 13% Reconciliation between GAAP and Non-GAAP projected sales growth: For the three months ending June 30, 2025 Net sales per guidance (midpoint) $ 62,545 Impact of currency exchange rate fluctuations (838 ) Adjusted projected net sales $ 61,707 For the three months ended June 30, 2024 Net sales as reported $ 55,849 Net impact of divestitures excluding currency (960 ) Adjusted net sales $ 54,889 Adjusted projected net sales increase for the three months ending June 30, 2025 $ 6,818 12% Reconciliation between GAAP and Non-GAAP projected sales growth: For the year ending December 31, 2025 Net sales per guidance (midpoint) $ 245,496 Impact of currency exchange rate fluctuations (1,464 ) Adjusted projected net sales $ 244,032 For the year ended December 31, 2024 Net sales as reported $ 219,863 Net impact of divestitures excluding currency (3,265 ) Adjusted net sales $ 216,598 Adjusted projected net sales increase for the year ending December 31, 2025 $ 27,434 13% CONTACT: CONTACT: Gregory Manker Director of Business Development and Investor Relations +1 781-362-1260 x 419 gmanker@ in to access your portfolio
Yahoo
18-04-2025
- Business
- Yahoo
Q4 Earnings Highlights: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables
Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at LeMaitre (NASDAQ:LMAT) and the best and worst performers in the surgical equipment & consumables - specialty industry. The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly. The 4 surgical equipment & consumables - specialty stocks we track reported a mixed Q4. As a group, revenues beat analysts' consensus estimates by 0.7% while next quarter's revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 22.3% since the latest earnings results. Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions. LeMaitre reported revenues of $55.72 million, up 14% year on year. This print fell short of analysts' expectations by 0.7%. Overall, it was a mixed quarter for the company with a solid beat of analysts' full-year EPS guidance estimates but a slight miss of analysts' EPS estimates. Chairman/CEO George LeMaitre said, '2024 was a productive year. More reps, higher ASPs, a better GM and controlled spending produced growth in sales (+14%), op. income (+42%) & EPS (+44%). $300mm of cash provides strategic optionality.' LeMaitre pulled off the highest full-year guidance raise of the whole group. Still, the market seems discontent with the results. The stock is down 19.7% since reporting and currently trades at $84.77. Is now the time to buy LeMaitre? Access our full analysis of the earnings results here, it's free. Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties. Intuitive Surgical reported revenues of $2.41 billion, up 25.2% year on year, outperforming analysts' expectations by 6.5%. The business had an incredible quarter with an impressive beat of analysts' sales volume and EPS estimates. Intuitive Surgical scored the biggest analyst estimates beat and fastest revenue growth among its peers. The stock is down 19.7% since reporting. It currently trades at $487.87. Is now the time to buy Intuitive Surgical? Access our full analysis of the earnings results here, it's free. With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE:TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide. Teleflex reported revenues of $795.4 million, up 2.8% year on year, falling short of analysts' expectations by 2.3%. It was a softer quarter as it posted a miss of analysts' constant currency revenue estimates. Teleflex delivered the weakest performance against analyst estimates and slowest revenue growth in the group. The stock is down 27.2% since the results and currently trades at $129.26. Read our full analysis of Teleflex's results here. Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments. Integra LifeSciences reported revenues of $442.6 million, up 11.5% year on year. This print came in 0.7% below analysts' expectations. Overall, it was a slower quarter as it also recorded a miss of analysts' full-year EPS guidance estimates. Integra LifeSciences had the weakest full-year guidance update among its peers. The stock is down 27.1% since reporting and currently trades at $16.06. Read our full, actionable report on Integra LifeSciences here, it's free. Thanks to the Fed's series of rate hikes in 2022 and 2023, inflation has cooled significantly from its post-pandemic highs, drawing closer to the 2% goal. This disinflation has occurred without severely impacting economic growth, suggesting the success of a soft landing. The stock market thrived in 2024, spurred by recent rate cuts (0.5% in September and 0.25% in November), and a notable surge followed Donald Trump's presidential election win in November, propelling indices to historic highs. Nonetheless, the outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. The path forward holds both optimism and caution as new policies take shape. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.
